Howard Kallender

1.2k total citations
34 papers, 944 citations indexed

About

Howard Kallender is a scholar working on Dermatology, Immunology and Allergy and Molecular Biology. According to data from OpenAlex, Howard Kallender has authored 34 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Dermatology, 11 papers in Immunology and Allergy and 9 papers in Molecular Biology. Recurrent topics in Howard Kallender's work include Dermatology and Skin Diseases (11 papers), Allergic Rhinitis and Sensitization (7 papers) and Food Allergy and Anaphylaxis Research (6 papers). Howard Kallender is often cited by papers focused on Dermatology and Skin Diseases (11 papers), Allergic Rhinitis and Sensitization (7 papers) and Food Allergy and Anaphylaxis Research (6 papers). Howard Kallender collaborates with scholars based in United States, Canada and United Kingdom. Howard Kallender's co-authors include Merrill L. Schaeffer, John T. Lonsdale, Patrick J. Brennan, Gautam Agnihotri, Harold Keer, Craig Volker, Stewart W. McCallum, Manish A. Shah, Robert Gagnon and James M. Ford and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Howard Kallender

34 papers receiving 920 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Howard Kallender United States	17	379	200	176	156	124	34	944
Federica Morandi United States	20	364 1.0×	129 0.6×	183 1.0×	96 0.6×	75 0.6×	65	1.2k
Xuemei Jiang China	19	435 1.1×	87 0.4×	144 0.8×	122 0.8×	239 1.9×	66	1.0k
Haitao Yu China	18	559 1.5×	199 1.0×	466 2.6×	72 0.5×	166 1.3×	42	1.2k
Seung Ok Lee South Korea	22	570 1.5×	274 1.4×	332 1.9×	205 1.3×	106 0.9×	83	1.6k
Mary Ferguson United States	14	557 1.5×	175 0.9×	168 1.0×	40 0.3×	123 1.0×	20	1.0k
Wen Yuan Chung United Kingdom	18	567 1.5×	289 1.4×	191 1.1×	240 1.5×	31 0.3×	60	1.5k
Rashmi Kaul India	17	278 0.7×	152 0.8×	77 0.4×	158 1.0×	79 0.6×	58	1.0k
Siddhartha Dutta Gupta India	15	431 1.1×	155 0.8×	100 0.6×	71 0.5×	29 0.2×	24	811
Masami Minemura Japan	16	238 0.6×	165 0.8×	71 0.4×	255 1.6×	61 0.5×	60	849
Steven Lacy United States	19	333 0.9×	419 2.1×	311 1.8×	112 0.7×	134 1.1×	29	1.2k

Countries citing papers authored by Howard Kallender

Since Specialization

Citations

This map shows the geographic impact of Howard Kallender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard Kallender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard Kallender more than expected).

Fields of papers citing papers by Howard Kallender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard Kallender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard Kallender. The network helps show where Howard Kallender may publish in the future.

Co-authorship network of co-authors of Howard Kallender

This figure shows the co-authorship network connecting the top 25 collaborators of Howard Kallender. A scholar is included among the top collaborators of Howard Kallender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard Kallender. Howard Kallender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Linda Stein, Robert Bissonnette, Seth Forman, et al.. (2025). A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis. American Journal of Clinical Dermatology. 26(2). 275–289. 6 indexed citations

Eichenfield, Lawrence F., Linda Stein Gold, Eric L. Simpson, et al.. (2025). Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study. Journal of the American Academy of Dermatology. 93(3). 689–698. 1 indexed citations

Eichenfield, Lawrence F., Eric L. Simpson, Kim Papp, et al.. (2024). Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. American Journal of Clinical Dermatology. 25(4). 669–683. 8 indexed citations

Simpson, Eric L., Leon Kircik, Andrew Blauvelt, et al.. (2024). Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies. Dermatology and Therapy. 14(8). 2139–2151. 2 indexed citations

Simpson, Eric L., Matthias Augustin, Diamant Thaçi, et al.. (2024). Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. American Journal of Clinical Dermatology. 26(1). 121–137. 5 indexed citations

Simpson, Eric L., Leon Kircik, Andrew Blauvelt, et al.. (2023). Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy. The Journal of Dermatology. 50(12). 1523–1530. 2 indexed citations

Eichenfield, Lawrence F., Linda Stein Gold, Kanwaljit Brar, et al.. (2022). 275 Effects of ruxolitinib cream on sleep and quality of life over 52 weeks in black patients with atopic dermatitis. Journal of Investigative Dermatology. 142(8). S47–S47. 1 indexed citations

Blauvelt, Andrew, Jacek C. Szepietowski, Kim Papp, et al.. (2022). 307 High-threshold responses to ruxolitinib cream in adolescents and adults with atopic dermatitis. Journal of Investigative Dermatology. 142(8). S52–S52. 1 indexed citations

Papp, Kim, Jacek C. Szepietowski, Leon Kircik, et al.. (2022). Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. Journal of the American Academy of Dermatology. 88(5). 1008–1016. 58 indexed citations

10.

Lickliter, Jason D., Hui Gan, Mark Voskoboynik, et al.. (2020). <p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. Drug Design Development and Therapy. Volume 14. 1177–1189. 26 indexed citations

11.

Yau, Thomas, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, et al.. (2016). A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 23(10). 2405–2413. 58 indexed citations

12.

Shah, Manish A., Zev A. Wainberg, Daniel V.T. Catenacci, et al.. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE. 8(3). e54014–e54014. 182 indexed citations

13.

Seiwert, Tanguy Y., John Sarantopoulos, Howard Kallender, et al.. (2012). Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 31(2). 417–424. 70 indexed citations

14.

Cecchi, Franco, Robert Gagnon, Howard Kallender, et al.. (2009). Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients. Molecular Cancer Therapeutics. 8(12_Supplement). B210–B210. 2 indexed citations

15.

Jhawer, Minaxi, Hedy L. Kindler, Zev A. Wainberg, et al.. (2009). Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. Journal of Clinical Oncology. 27(15_suppl). 4502–4502. 43 indexed citations

16.

Campobasso, Nino, et al.. (2004). Staphylococcus aureus 3-Hydroxy-3-methylglutaryl-CoA Synthase. Journal of Biological Chemistry. 279(43). 44883–44888. 52 indexed citations

17.

Schaeffer, Merrill L., Jeffrey D. Carson, Howard Kallender, & John T. Lonsdale. (2004). Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis. Tuberculosis. 84(6). 353–360. 7 indexed citations

18.

Schaeffer, Merrill L., Gautam Agnihotri, Howard Kallender, Patrick J. Brennan, & John T. Lonsdale. (2001). Expression, purification, and characterization of the Mycobacterium tuberculosis acyl carrier protein, AcpM. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1532(1-2). 67–78. 31 indexed citations

19.

Schaeffer, Merrill L., Gautam Agnihotri, Craig Volker, et al.. (2001). Purification and Biochemical Characterization of theMycobacterium tuberculosis β-Ketoacyl-acyl Carrier Protein Synthases KasA and KasB. Journal of Biological Chemistry. 276(50). 47029–47037. 115 indexed citations

20.

Jenkins, Owen, David L. Earnshaw, Antonio Del Vecchio, et al.. (1996). Characterization of the helicase and ATPase activity of human papillomavirus type 6b E1 protein. Journal of General Virology. 77(8). 1805–1809. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact